Autohome Inc. (ATHM) Is At $104.05 Formed Wedge; Vanda Pharmaceuticals Inc. (VNDA) Had 8 Bullish Analysts

Autohome Inc. (ATHM) formed wedge up with $110.29 target or 6.00% above today’s $104.05 share price. Autohome Inc. (ATHM) has $12.22B valuation. The stock decreased 0.82% or $0.86 during the last trading session, reaching $104.05. About 505,968 shares traded. Autohome Inc. (NYSE:ATHM) has risen 162.88% since May 13, 2017 and is uptrending. It has outperformed by 151.33% the S&P500.

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 24 analyst reports since September 2, 2015 according to SRatingsIntel. The firm has “Buy” rating by Brean Capital given on Wednesday, October 21. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Market Outperform” rating given on Friday, August 26 by JMP Securities. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. Oppenheimer maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Sunday, November 12. Oppenheimer has “Buy” rating and $25.0 target. Piper Jaffray initiated Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Tuesday, June 27. Piper Jaffray has “Buy” rating and $2300 target. Jefferies maintained it with “Buy” rating and $21.0 target in Monday, September 4 report. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Piper Jaffray on Thursday, August 3. As per Thursday, October 19, the company rating was maintained by Piper Jaffray. Seaport Global maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Wednesday, February 28. Seaport Global has “Buy” rating and $21.0 target. The rating was initiated by Aegis Capital on Wednesday, November 9 with “Buy”. See Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings:

05/03/2018 Broker: Oppenheimer Rating: Buy New Target: $27.0 Maintain
28/02/2018 Broker: Seaport Global Rating: Buy New Target: $21.0 Maintain
13/02/2018 Broker: Jefferies Rating: Buy New Target: $20.0 Maintain
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $20 Initiates Coverage On
08/01/2018 Broker: Oppenheimer Rating: Buy Maintain

Among 12 analysts covering Autohome Inc (NYSE:ATHM), 8 have Buy rating, 2 Sell and 2 Hold. Therefore 67% are positive. Autohome Inc had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Autohome Inc. (NYSE:ATHM) has “Underperform” rating given on Tuesday, June 28 by Credit Suisse. JP Morgan initiated the shares of ATHM in report on Tuesday, February 23 with “Neutral” rating. The rating was downgraded by Credit Agricole to “Underperform” on Monday, February 22. The stock of Autohome Inc. (NYSE:ATHM) earned “Buy” rating by CLSA on Tuesday, November 14. The stock of Autohome Inc. (NYSE:ATHM) earned “Buy” rating by Citigroup on Thursday, October 29. The stock has “Buy” rating by Citigroup on Tuesday, January 2. The stock of Autohome Inc. (NYSE:ATHM) has “Outperform” rating given on Friday, November 6 by Credit Agricole. Benchmark maintained Autohome Inc. (NYSE:ATHM) rating on Wednesday, November 8. Benchmark has “Buy” rating and $76.0 target. JP Morgan initiated the stock with “Neutral” rating in Wednesday, August 31 report. The firm has “Buy” rating given on Monday, June 6 by Brean Capital.

The stock increased 3.74% or $0.6 during the last trading session, reaching $16.65. About 364,980 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 15.63% since May 13, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $867.64 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Investors sentiment decreased to 1.17 in Q4 2017. Its down 0.26, from 1.43 in 2017Q3. It turned negative, as 19 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 39.77 million shares or 2.28% more from 38.89 million shares in 2017Q3 were reported. Fmr Ltd Liability Company holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 1.31M shares. Cheyne Mngmt (Uk) Llp accumulated 74,000 shares. Oberweis Asset Inc, a Illinois-based fund reported 10,700 shares. Proshare Advisors Limited Liability has 30,744 shares. Prudential Fincl Inc has invested 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). State Street stated it has 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Illinois-based Group Incorporated One Trading L P has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Jpmorgan Chase & has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Jacobs Levy Equity Mngmt Inc reported 22,490 shares. The Texas-based Teacher Retirement Of Texas has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Wells Fargo And Mn accumulated 174,222 shares. Secor Capital Limited Partnership holds 0.08% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) or 127,277 shares. 50,000 are held by Weiss Multi. Schwab Charles Investment Mgmt Inc accumulated 482,012 shares or 0.01% of the stock.

More recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Globenewswire.com which released: “Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals …” on May 10, 2018. Also Seekingalpha.com published the news titled: “Vanda Pharmaceuticals’ (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings” with publication date: May 02, 2018 was also an interesting one.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart